Somewhat Positive Press Coverage Somewhat Unlikely to Impact Cellular Biomedicine Group (CBMG) Stock Price

Media stories about Cellular Biomedicine Group (NASDAQ:CBMG) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cellular Biomedicine Group earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.9069538419175 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several research analysts have recently issued reports on the company. BidaskClub cut Cellular Biomedicine Group from a “buy” rating to a “hold” rating in a research note on Wednesday, May 9th. Zacks Investment Research raised Cellular Biomedicine Group from a “sell” rating to a “hold” rating in a research note on Tuesday, May 29th. ValuEngine raised Cellular Biomedicine Group from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Maxim Group reaffirmed a “hold” rating on shares of Cellular Biomedicine Group in a research note on Friday, June 15th. Finally, B. Riley reaffirmed a “buy” rating on shares of Cellular Biomedicine Group in a research note on Friday, March 16th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $25.00.

Cellular Biomedicine Group traded down $0.15, hitting $18.85, during trading hours on Wednesday, MarketBeat.com reports. 14,946 shares of the stock traded hands, compared to its average volume of 58,527. Cellular Biomedicine Group has a one year low of $8.30 and a one year high of $22.75. The stock has a market capitalization of $332.28 million, a P/E ratio of -10.59 and a beta of 3.40.

Cellular Biomedicine Group (NASDAQ:CBMG) last announced its earnings results on Monday, May 7th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.05). Cellular Biomedicine Group had a negative net margin of 9,594.83% and a negative return on equity of 45.67%. The firm had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.10 million. sell-side analysts expect that Cellular Biomedicine Group will post -1.72 EPS for the current year.

Cellular Biomedicine Group Company Profile

Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis.

Insider Buying and Selling by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)

Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply